Biogen Inc.

Biogen Inc. is a biopharmaceutical company that discovers, develops, manufactures, and delivers therapies for neurological and neurodegenerative diseases across the United States, Europe, Asia, and other international markets. Its portfolio includes treatments for multiple sclerosis such as TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI; SPINRAZA for spinal muscular atrophy; SKYCLARYS for Friedreich's Ataxia; QALSODY for amyotrophic lateral sclerosis; LEQEMBI for Alzheimer's disease; and ZURZUVAE for postpartum depression. Biogen Inc. also offers RITUXAN for non-Hodgkin's lymphoma, chronic lymphocytic leukemia, rheumatoid arthritis, and other conditions, alongside biosimilars like BENEPALI, IMRALDI, and FLIXABI, and FUMADERM for plaque psoriasis. The company focuses on advancing therapies in areas like autoimmune diseases and neurodegeneration, serving patients through innovative treatments that address unmet medical needs in these critical therapeutic areas. Founded in 1977 and headquartered in Cambridge, Massachusetts, Biogen Inc. plays a significant role in the global biotechnology sector by providing specialized medicines for complex disorders.